Press Release

McKesson Ventures Invests as Clinical Ink Debuts Lunexis ePRO+ Solution
Mixed Modalities Allow Users to Switch Between Smartphones, Tablets, and Web Any Time

HORSHAM, Pa.; Dec. 3, 2020 – Clinical Ink, a global clinical trial technology company, today announced an investment from McKesson Ventures alongside its significantly enhanced electronic patient reported outcome (ePRO) module. Lunexis™ ePRO+ is part of a unified …

McKesson Ventures Invests as Clinical Ink Debuts Lunexis ePRO+ Solution
Mixed Modalities Allow Users to Switch Between Smartphones, Tablets, and Web Any Time
Read More…

Scroll to Top